Phase II
Enanta Pharmaceuticals, Inc. announced that new data from its Phase 2a Human Challenge Study of EDP-938 is being presented as a late-breaker oral presentation today at IDWeek™ 2019 in Washington, D.C. EDP-938 is Enanta’s lead N-protein inhibitor being developed for the treatment of RSV infection.
IXALTIS presents positive results from phase 2 studies for its lead compound Litoxetine, a potential “first in class” treatment for urinary incontinence.
A multicenter, international, single-arm, Phase II trial of lurbinectedin in progressive Malignant Pleural Mesothelioma (MPM) has been presented at ESMO.
Evgen Pharma plc announces that the clinical data from the completed open-label Phase II STEM trial was presented in poster format yesterday at the 2019 European Society of Medical Oncology Congress in Barcelona.
NOXXON Pharma N.V. announced the latest clinical results from the Phase 1/2 study of NOX-A12 in combination with Keytruda® in patients with microsatellite-stable, metastatic pancreatic and colorectal cancer in a poster presentation at the European Society for Medical Oncology Congress in Barcelona, Spain.
Data shared in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of death by 36% (HR=0.64, p=0.079 one-sided)
Immutep Limited announces that the requisite number of predefined patient responses has been exceeded in cohort 1 of Part A) of the TACTI-002 Phase II clinical trial based on an interim analysis.
Adrenomed AG, the vascular integrity company, announced the successful completion of patient enrollment in the proof-of-concept Phase II trial, AdrenOSS-2, evaluating Adrecizumab in patients with early septic shock.
NorthSea Therapeutics B.V. announces dosing of the first patient with icosabutate in a phase 2b dose ranging study.
Summit Therapeutics plc and collaborators will present new data analyses from the Phase 2 clinical trial of ridinilazole in patients with C. difficile infection (‘CDI’) at ID Week 2019, taking place 2-6 October 2019 in Washington, DC.
PRESS RELEASES